These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27502323)

  • 21. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of surgical intervention and stereotactic body radiation therapy for stage I lung cancer in high-risk patients: a decision analysis.
    Puri V; Crabtree TD; Kymes S; Gregory M; Bell J; Bradley JD; Robinson C; Patterson GA; Kreisel D; Krupnick AS; Meyers BF
    J Thorac Cardiovasc Surg; 2012 Feb; 143(2):428-36. PubMed ID: 22169443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
    Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials.
    Mouillet G; Monnet E; Milleron B; Puyraveau M; Quoix E; David P; Ducoloné A; Molinier O; Zalcman G; Depierre A; Westeel V;
    J Thorac Oncol; 2012 May; 7(5):841-9. PubMed ID: 22722786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
    Brown T; Boland A; Bagust A; Oyee J; Hockenhull J; Dundar Y; Dickson R; Ramani VS; Proudlove C
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):71-9. PubMed ID: 21047494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost of combined modality interventions for stage III non-small-cell lung cancer.
    Evans WK; Will BP; Berthelot JM; Earle CC
    J Clin Oncol; 1997 Sep; 15(9):3038-48. PubMed ID: 9294466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
    Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
    J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
    Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
    J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral gene expression of 5-fluorouracil pharmacokinetics-related enzymes in stage I and II non-small cell lung cancer patients treated with uracil-tegafur after surgery: a prospective multi-institutional study in Japan.
    Eguchi K; Oyama T; Tajima A; Abiko T; Sawafuji M; Horio H; Hashizume T; Matsutani N; Kato R; Nakayama M; Kawamura M; Kobayashi K
    Lung Cancer; 2015 Jan; 87(1):53-8. PubMed ID: 25468199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of the 21-gene assay for guiding adjuvant chemotherapy decisions in early breast cancer.
    Paulden M; Franek J; Pham B; Bedard PL; Trudeau M; Krahn M
    Value Health; 2013; 16(5):729-39. PubMed ID: 23947965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of adjuvant chemotherapy for non-small cell lung cancer assessed by metastatic potential associated with ACTN4.
    Miura N; Kamita M; Kakuya T; Fujiwara Y; Tsuta K; Shiraishi H; Takeshita F; Ochiya T; Shoji H; Huang W; Ohe Y; Yamada T; Honda K
    Oncotarget; 2016 May; 7(22):33165-78. PubMed ID: 27121206
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectivenes of paclitaxel plus cisplatin in advanced non-small-cell lung cancer.
    Earle CC; Evans WK
    Br J Cancer; 1999 May; 80(5-6):815-20. PubMed ID: 10360660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.
    Roth JA; Billings P; Ramsey SD; Dumanois R; Carlson JJ
    Oncologist; 2014 May; 19(5):466-76. PubMed ID: 24710309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of modified fractionation radiotherapy versus conventional radiotherapy for unresected non-small-cell lung cancer patients.
    Ramaekers BL; Joore MA; Lueza B; Bonastre J; Mauguen A; Pignon JP; Le Pechoux C; De Ruysscher DK; ; Grutters JP
    J Thorac Oncol; 2013 Oct; 8(10):1295-307. PubMed ID: 24457241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC.
    Vergnenegre A; Massuti B; de Marinis F; Carcereny E; Felip E; Do P; Sanchez JM; Paz-Arez L; Chouaid C; Rosell R;
    J Thorac Oncol; 2016 Jun; 11(6):801-7. PubMed ID: 26899757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.
    Booth CM; Shepherd FA; Peng Y; Darling G; Li G; Kong W; Mackillop WJ
    J Thorac Oncol; 2012 Mar; 7(3):559-66. PubMed ID: 22307012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
    Strauss GM; Herndon JE; Maddaus MA; Johnstone DW; Johnson EA; Harpole DH; Gillenwater HH; Watson DM; Sugarbaker DJ; Schilsky RL; Vokes EE; Green MR
    J Clin Oncol; 2008 Nov; 26(31):5043-51. PubMed ID: 18809614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer.
    Wang H; Zeng C; Li X; Wang Y; Li X; Ge W
    Future Oncol; 2019 Jan; 15(2):181-191. PubMed ID: 30320506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.